Balyasny Asset Management
JANX icon

Balyasny Asset Management’s Janux Therapeutics JANX Stock Holding History

Balyasny Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Sell
211,635
-878,512
-81% -$12.7M ﹤0.01% 1585
2026
Q1 		$15.2M Buy
1,090,147
+204,596
+23% +$2.81M 0.02% 811
2025
Q4 		$12.2M Buy
+885,551
New +$20.8M 0.02% 934
2025
Q3 		– Sell
-10,054
Closed -$232K – 3183
2025
Q2 		$232K Buy
+10,054
New +$265K ﹤0.01% 2558
2024
Q4 		– Sell
-63,215
Closed -$2.87M – 2999
2024
Q3 		$2.87M Buy
+63,215
New +$2.75M ﹤0.01% 1518
2022
Q4 		– Sell
-12,182
Closed -$165K – 2998
2022
Q3 		$165K Buy
+12,182
New +$163K ﹤0.01% 2341

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Balyasny Asset Management's JANX Position: Q2 2026 in Review

Balyasny Asset Management reduced its Janux Therapeutics (JANX) stake by 81% in Q2 2026, selling an estimated $12.7M and leaving 211,635 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1585.

Balyasny Asset Management first reported a position in JANX in Q3 2022 and has held it in 6 quarters since. The position peaked at $15.2M in Q1 2026. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Balyasny Asset Management held 211,635 shares of Janux Therapeutics worth $3.25M as of Q2 2026.
  • Balyasny Asset Management sold 878,512 Janux Therapeutics shares in Q2 2026, an estimated $12.7M.
  • Janux Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1585 holding.
  • Balyasny Asset Management first reported a position in Janux Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • Balyasny Asset Management's Janux Therapeutics position peaked at $15.2M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.